exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088031 RNA Name: hsa-miR-31-5p RNA Type: miRNA Chromosome: chr9 Starnd: - Coordinate: Start Site(bp): 21512158 End Site(bp): 21512178 External Links: hsa-miR-31-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABHD4 chr14 22598237 22613215 + ANKRD52 chr12 56237807 56258384 - BACH2 chr6 89926528 90296908 - CHD1 chr5 98853985 98928957 - CTNND1 chr11 57753243 57819546 + FAM222B chr17 28755978 28855232 - FURIN chr15 90868588 90883458 + GRK2 chr11 67266473 67286556 + HACD3 chr15 65530418 65578349 + HOXA7 chr7 27153716 27157936 - KIF3B chr20 32277651 32335011 + LONRF1 chr8 12721906 12756073 - MAP3K14 chr17 45263119 45317029 - PATL1 chr11 59636716 59669037 - PLCB1 chr20 8077251 8968360 + PPP1R3C chr10 91628442 91633071 - PRRC2B chr9 131373636 131500197 + RTL8B chrX 135020513 135022542 - RTL8C chrX 135032355 135033546 + SERF2 chr15 43777087 43802589 + SMAD3 chr15 67063763 67195169 + TRIM35 chr8 27284886 27311272 - XPNPEP3 chr22 40857077 40932815 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001728 chr7 99695763 99695845 - hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0000241 chr10 70847874 70856944 + hsa_circ_0000931 chr19 38226804 38231095 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004832.5 chr22 30420512 30420912 + AC016876.2 chr17 7581964 7584086 - AC074117.1 chr2 27356246 27367622 + AC087477.2 chr15 96354237 96405235 + GAS5 chr1 173858559 173868882 - MAGI2-AS3 chr7 79452877 79471208 + MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.